Mounjaro side effects: the common, the rare and the red flags

Mounjaro (tirzepatide) has a feature the other weight loss jabs lack: it activates two receptors, the one for GLP-1 and the one for a second gut hormone, GIP. The question comes up quickly, in consulting rooms and on forums alike. Does a double action mean double the trouble? The Mounjaro side effects described in the UK product information are of the same kind as those of its cousins, mostly digestive, and they sort into four tiers of frequency.

That document draws on 14 phase 3 studies in which 15,169 adults received tirzepatide. We follow it tier by tier.

Mounjaro side effects in more than one person in ten

The "very common" effects of Mounjaro are nausea and diarrhoea, whatever it is prescribed for. In people treated for their weight, vomiting, abdominal pain and constipation join them. In adults treated for type 2 diabetes, those three drop down a tier, to "common".

The product information states that these reactions are mostly mild or moderate, and that nausea, diarrhoea and vomiting occur mainly while the dose is being increased, then decline over time.

The trial that tells us most about people treated for weight enrolled 2,539 adults without diabetes, split between three doses of tirzepatide and placebo for 72 weeks. It is SURMOUNT-1, published in the New England Journal of Medicine in 2022. The UK product information pools its tolerability data with those of SURMOUNT-2, run in adults who also had type 2 diabetes.

Placebo is not symptom-free: nearly one participant in three had a digestive complaint on it. And the distance between those who have symptoms and those who stop is considerable, since these complaints were mild in 61.0% of cases and moderate in 34.4%.

In adults treated for diabetes the figures are lower: 12.2 to 18.3% had nausea depending on the dose, against 4.3% on placebo.

One last "very common" effect concerns only some people with diabetes. When tirzepatide is combined with a sulfonylurea or insulin, hypos move into this category, and the product information refers to the doctor for adjusting those other treatments.

Up to one person in ten

This is the fullest tier. It holds the rest of the digestive picture, indigestion, bloating, wind, belching and reflux, along with fatigue and injection site reactions, which were mild in 91% of cases.

Three effects are attached specifically to weight management: dizziness, low blood pressure and hair loss. On the last of these the UK document gives a figure: 4.9% of participants on tirzepatide in the weight management studies, against 1.0% on placebo. It was mostly mild, most people recovered while staying on treatment, and nobody left a study because of it. Hair shedding tends to accompany any large, fast weight loss.

Gallstones are also "common" in people treated for weight, and "uncommon" in those treated for diabetes. Acute gallbladder disease was reported in 2.0% of treated participants and 1.6% of those on placebo in the weight management studies. The document notes that these events were positively correlated with the amount of weight lost, which ties them to the slimming as much as to the molecule.

Ordinary allergic reactions, a rash or itching, sit here too. So do findings you will not necessarily feel: raised pancreatic enzymes on a blood test, and a rise in calcitonin, a hormone made by the thyroid. The product information reports thyroid tumours in rats given tirzepatide and states that the relevance of that finding for humans is unknown. It is a point to raise with your prescriber if you have a history of thyroid disease.

Up to one person in a hundred

The "uncommon" effects include the one that causes most concern, acute pancreatitis. Its warning sign is severe, persistent pain in the abdomen that may spread to the back. In January 2026 the MHRA strengthened the pancreatitis warning on all GLP-1 medicines, tirzepatide included, noting rare reports of necrotising and fatal cases among the Yellow Cards it has received.

Altered taste, changes in skin sensation and delayed emptying of the stomach are in the same tier. The last explains why you are asked to mention the treatment before any anaesthetic. A faster pulse belongs here as well for people treated for weight, with a mean rise of 3 beats per minute in those studies.

Up to one person in a thousand

A single type of effect occupies the "rare" category: severe allergic reaction, anaphylaxis or angioedema, reported after the medicine went on sale.

The Mounjaro product information does not list the optic nerve condition NAION or bowel obstruction, both of which appear for semaglutide. The European review of NAION that concluded in 2025 concerned that other molecule. The list can change: tirzepatide still carries the black triangle of medicines under additional monitoring.

The signs that are not up for discussion

Two situations demand an immediate response.

Severe pain in the stomach and back that does not pass: seek urgent medical attention. Difficulty breathing, rapid swelling of the lips, tongue or throat, trouble swallowing, a pounding heart: call 999.

Dehydration creeps up more quietly. The product information explains that vomiting and diarrhoea can cost enough fluid to impair the kidneys, and asks patients to guard against it. Vomiting that goes on, being unable to keep drinks down, feeling faint when you stand up: these justify contacting your prescriber, your GP or NHS 111 the same day. If your Mounjaro comes from a private provider, say so, because it may not appear on your NHS record.

The pill, pregnancy and alcohol: what the texts say

On contraception the UK position is specific. The product information describes a study in which a single dose of tirzepatide reduced and delayed the absorption of a combined pill, and advises women with obesity or overweight who use oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase. The MHRA repeated that advice in guidance published in June 2025.

Mounjaro should not be used during pregnancy, and the product information asks for it to be stopped at least one month before a planned pregnancy. The MHRA also advises against GLP-1 medicines while breastfeeding. All of this deserves a proper conversation with your prescriber, ideally before the first injection.

On alcohol the product information gives no particular warning, which is not the same as a green light. Our article on Mounjaro and alcohol sets out what is known.

Eating and drinking through the difficult weeks

The only levers within everyone's reach are fluids and the way you eat. Drink regularly, in small amounts if your stomach protests. Cut portions, slow down, and save fatty or very large meals for the days when all is well.

These are general pointers: pharmacists and prescribers know how to adapt them, and they are the people to see if symptoms stop you eating. The detail is in our GLP-1 diet guide. The guide to GLP-1 side effects sets the product information for each medicine side by side, and the one on Wegovy side effects covers semaglutide.

Frequently asked questions

What are the most common side effects of Mounjaro?

Nausea and diarrhoea, classed as "very common" in the product information. In people treated for their weight, vomiting, abdominal pain and constipation fall into the same category.

How long do Mounjaro side effects last?

They appear mainly at the start of treatment and while the dose is being increased, according to the product information, and become less frequent after that in most patients. In the SURMOUNT-1 trial, that dose-escalation phase lasted up to 20 weeks.

Does Mounjaro cause hair loss?

Hair loss is classed as "common" in people treated for weight management: 4.9% reported it in the studies, against 1.0% on placebo. It was mostly mild, and most people recovered while continuing treatment.

Does Mounjaro have more side effects than Wegovy?

The product information cannot settle that. The figures come from separate trials, with different populations and durations, and cannot be compared directly. The profile is of the same kind, dominated by digestive complaints.

Does Mounjaro stop the pill working?

It may make oral contraceptives less effective in women who are overweight. The UK advice is to use a non-oral method, or add a barrier method such as condoms, for four weeks after starting Mounjaro and after each dose increase. Your prescriber or pharmacist can advise on the options.

This article is for information only and is no substitute for advice from a healthcare professional. Never change your treatment without talking to your doctor.